Trump expands tariffs into pharmaceuticals

Pharmaceuticals just got pulled into the same trade machine that already hit steel, aluminum, and copper. But this one is bigger for consumers — because the product is medicine, not metal. On April 2, President Trump imposed new tariffs on patented imported drugs and their ingredients under Section 232, the national-security trade law his administration has been using more aggressively across strategic industries. The twist is that this is not just a tariff story. It is also a drug-pricing story. (whitehouse.gov) ### What actually changed? The administration set a 100% tariff on patented pharmaceutical products and ingredients. Large companies get 120 days before it kicks in. Smaller comp(whitehouse.gov) of the market. (whitehouse.gov) ### Why use Section 232 for drugs? Section 232 is the same national-security authority Trump has used for other industrial imports. The White House says imported pharmaceuticals (whitehouse.gov)ented drugs sold domestically are made outside the U.S., and only 15% of patented APIs by volume are produced for the U.S. market at home. (whitehouse.gov) ### Why is this more than a normal tariff? Because the tariff is really a pressure tool with off-ramps. If a company signs both an onshoring agreement with Commerce and a most-favored-nation pricing agreement with HHS, the tariff c(whitehouse.gov)ica, and charge Americans closer to the lowest rich-country price. (whitehouse.gov) ### What is the MFN piece doing here? MFN pricing means the White House wants U.S. patients or programs to pay prices tied to the lowest prices charged in comparable developed co(whitehouse.gov)s negotiating with the administration. Basically, tariffs and pricing are no longer separate lanes. They are one package. (whitehouse.gov) ### Who gets hit hardest? The obvious losers are branded-drug companies that still rely on overseas plants and have not secured favorable terms with Washington. The structure also favors companies that alrea(whitehouse.gov)ates matter. (whitehouse.gov) ### Why are some countries treated differently? The administration carved out lower rates for some trade-partner countries. Products from the EU, Japan, Korea, Switzerland, and L(whitehouse.gov) shaped by bilateral leverage. (whitehouse.gov) ### What does this do to the industry? It pushes drugmakers toward a more fragmented map. Companies may manufacture more in the U.S., launch in some markets before others, or ret(whitehouse.gov) can change incentives quickly, but the physical system moves slowly. (whitehouse.gov) ### Bottom line? Trump has expanded tariffs from classic heavy industry into prescription drugs — and that changes the meaning of U.S. trade policy. The new model is not just “ta(whitehouse.gov) policy lever. (whitehouse.gov)